Subclinical myopathy in a child with neutral lipid storage disease and mutations in the PNPLA2 gene.

[1]  G. Matsumiya,et al.  Triglyceride deposit cardiomyovasculopathy. , 2008, The New England journal of medicine.

[2]  Y. Gong,et al.  Novel PNPLA2 gene mutations in Chinese Han patients causing neutral lipid storage disease with myopathy , 2012, Journal of Human Genetics.

[3]  S. Dimauro,et al.  A novel mutation in PNPLA2 leading to neutral lipid storage disease with myopathy. , 2012, Archives of neurology.

[4]  D. Turnbull,et al.  The phenotypic spectrum of neutral lipid storage myopathy due to mutations in the PNPLA2 gene , 2011, Journal of Neurology.

[5]  Y. Yuan,et al.  A novel PNPLA2 mutation causes neutral lipid storage disease with myopathy (NLSDM) presenting muscular dystrophic features with lipid storage and rimmed vacuoles. , 2010, Clinical neuropathology.

[6]  P. Laforêt,et al.  Disorders of muscle lipid metabolism: Diagnostic and therapeutic challenges , 2010, Neuromuscular Disorders.

[7]  S. Dimauro,et al.  Neutral lipid storage disease with subclinical myopathy due to a retrotransposal insertion in the PNPLA2 gene , 2010, Neuromuscular Disorders.

[8]  C. Angelini,et al.  EFNS guidelines on the diagnostic approach to pauci‐ or asymptomatic hyperCKemia , 2010, European journal of neurology.

[9]  R. Zechner,et al.  Neutral lipid storage disease: genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI-58/ABHD5. , 2009, American journal of physiology. Endocrinology and metabolism.

[10]  I. Nonaka,et al.  Clinical and genetic analysis of lipid storage myopathies , 2009, Muscle & nerve.

[11]  S. Dimauro,et al.  Novel mutations in the adipose triglyceride lipase gene causing neutral lipid storage disease with myopathy. , 2008, Biochemical and biophysical research communications.

[12]  S. Dimauro,et al.  Lipid storage myopathies , 2008, Current opinion in neurology.

[13]  M. Gaeta,et al.  Opposed-phase MR imaging of lipid storage myopathy in a case of Chanarin–Dorfman disease , 2008, Skeletal Radiology.

[14]  R. Takayanagi,et al.  The lack of the C-terminal domain of adipose triglyceride lipase causes neutral lipid storage disease through impaired interactions with lipid droplets. , 2008, The Journal of clinical endocrinology and metabolism.

[15]  S. Dimauro,et al.  Clinical and genetic characterization of Chanarin-Dorfman syndrome. , 2008, Biochemical and biophysical research communications.

[16]  J. R. McMillan,et al.  Novel duplication mutation in the patatin domain of adipose triglyceride lipase (PNPLA2) in neutral lipid storage disease with severe myopathy , 2007, Muscle & nerve.

[17]  M. Lathrop,et al.  The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy , 2007, Nature Genetics.

[18]  G. Bernardi,et al.  High plasma creatine kinase: review of the literature and proposal for a diagnostic algorithm , 2006, Neurological Sciences.

[19]  G. Bydder,et al.  A short protocol for muscle MRI in children with muscular dystrophies. , 2002, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[20]  J. Weissenbach,et al.  Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. , 2001, American journal of human genetics.

[21]  M. Barnes.  European Federation of Neurological Societies Task Force , 1997 .